Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MTTP | P55157 | 4/20 | 0.43 |
| ▸ | APOB | P04114 | 2/20 | 0.43 |
| ▸ | SMO | Q99835 | 8/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3345320 | 0.84 | NPC1 (0.47) | NPC1RAB9APAX8MEN1HSP90AA1 | |
| Trifluoroacetic Acid SCHEMBL3345474 | 0.82 | SLC2A1 (0.46) | MTTPAPOBHDAC1SLC2A1KDM1A | |
| SCHEMBL3339104 | 0.82 | HDAC1 (0.51) | NPC1RAB9APAX8MEN1HSP90AA1 | |
| SCHEMBL12651277 | 0.80 | KDM1A (0.50) | HDAC1FGFR3KDRKDM1A | |
| Trifluoroacetic Acid SCHEMBL16195088 | 0.70 | SLC2A1 (0.53) | RAB9AMEN1KMT2AMTTPAPOB | |
| Trifluoroacetic Acid SCHEMBL3337454 | 0.70 | SLC2A1 (0.55) | RAB9AMEN1KMT2AMTTPAPOB | |
| SCHEMBL13137147 | 0.69 | GRIN2B (0.39) | RAB9AMEN1KMT2AHDAC1 | |
| Hydrochloric Acid SCHEMBL3159892 | 0.69 | GRIN2B (0.38) | RAB9AMEN1KMT2AHDAC1 | |
| Trifluoroacetic Acid SCHEMBL1790201 | 0.68 | SLC2A1 (0.58) | RAB9AMEN1KMT2AMTTPAPOB | |
| Trifluoroacetic Acid SCHEMBL3342448 | 0.68 | SLC2A1 (0.53) | RAB9AMEN1KMT2AMTTPAPOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC | 2014-10-30 | — | — | US | disclosed |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | IGNAR DIANE MICHELE | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRD1, OPRK1 | NPC1 3112/4885RAB9A 2340/4885PAX8 1560/4885 |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | OPRL1, OPRM1, OPRK1 | NPC1 3467/4885RAB9A 1186/4885PAX8 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.